{"id":"W4233437943","doi":"10.1016/j.annonc.2021.07.011","title":"Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’","year":2021,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Oncology; Internal medicine; Cancer; Hormone receptor; Progression-free survival; Breast cancer; Metastatic breast cancer; Estrogen receptor; Epidermal growth factor receptor; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00154323,0.001176515,0.005873055,0.0004979062,0.0002222884,0.00003960439,0.0006569717,0.0008817784,0.00127733],"category_scores_gemma":[0.0004707633,0.0008351487,0.0004829239,0.0007776457,0.0007978288,0.0003149985,0.0001284376,0.001599679,0.000005995671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001307658,"about_ca_system_score_gemma":0.003442058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00105767,"about_ca_topic_score_gemma":0.0005732753,"domain_scores_codex":[0.9925432,0.001650698,0.001995264,0.001364909,0.0009360673,0.001509903],"domain_scores_gemma":[0.993474,0.001330768,0.001881175,0.0007491178,0.002068732,0.0004962119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8827624,0.001993251,0.000004534809,0.0002471267,0.002999646,0.0001498499,0.006274825,0.00002535079,0.01017125,0.0002017898,0.07773694,0.017433],"study_design_scores_gemma":[0.8634213,0.02883288,0.001117841,0.0008930301,0.0005539909,0.0001070598,0.002640124,0.00001628735,0.002037138,0.000373594,0.09888764,0.00111907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7840883,0.01365441,0.001329651,0.07475217,0.02924568,0.0505024,0.03964064,0.0003725425,0.006414206],"genre_scores_gemma":[0.7423548,0.0271593,0.007761402,0.03174859,0.01399599,0.04743885,0.02967454,0.001887237,0.09797928],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09156508,"threshold_uncertainty_score":0.9996356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05281472117392018,"score_gpt":0.3807381026792624,"score_spread":0.3279233815053423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}